Healthtech VCLink’s Post

📢 Calling all California-based life sciences startups! California Life Sciences (CLS) is thrilled to announce that we are now accepting pitch applications for our exclusive Investor Partnering Forum, taking place just before the highly anticipated Innovation Showcase. This is a unique opportunity for emerging startups to connect with a curated group of investors, each investor selects up to six companies for one-on-one, 20-minute in-person meetings. Confirmed Investors: AbbVie Ventures, Astellas Pharma Venture Management, Boehringer Ingelheim Venture Fund, Chiesi Global Rare Diseases, Civilization Ventures, Remiges Ventures, Inc., Servier Pharmaceuticals, and Xontogeny. At CLS, we are dedicated to advancing the innovation ecosystem in California, fostering growth, and empowering startups in the life sciences sector. If you're ready to accelerate your journey and connect with key investors, apply today! 🔗Learn more & apply: https://bit.ly/4e2sQcR #Innovation #CaliforniaLifeSciences #partneringforum #pitchyourstartup

🔬 Fundraising by healthcare startups in the second half of July 🌍 #Biotech 🇫🇷 Apmonia Therapeutics: drug discovery platform to fight cancer by focusing on tumor extracellular matrix disruption 💶 Amount raised: €7M in Series A 👥 Investors: EIC through its Accelerator fund 🇺🇸 CatalYm GmbH: company developing new cancer immunotherapies 💶 Amount raised: €150M in Series D 👥 Investors: JEITO, Canaan, Bioqube Ventures, Forbion, Omega Funds, Gilde Healthcare, & historical investors #Medtech 🇫🇷/🇩🇪 TRiCares GmbH: company specializing in minimally invasive treatment of tricuspid regurgitation 💶 Amount raised: €50M in Series D 👥 Investors: a single industrial player #Digitalhealth 🇺🇸 Thyme Care: oncology management platform for personalised care 💶 Amount raised: €52M in Series C 👥 Investors: CVS Health, Town Hall Ventures, a16z Bio + Health, AlleyCorp, Echo Health Ventures, Frist Cressey Ventures & Foresite Capital 🇺🇸 Huma: medical software that, coupled with a mobile app and connected objects, enables remote patient monitoring 💶 Amount raised: €74M in Series D 👥 Investors: AstraZeneca, HAT SGR, Hitachi Ventures & Bayer 🔍 A stronger focus on oncology (3 out of 5 funds raised) 📊 According to the latest estimates published by the IARC - International Agency for Research on Cancer / World Health Organization: - 🌍 Nearly 20 million new cases of cancer would have been diagnosed worldwide by 2022; - 📈 9.7 million people have died from it.

Could City Therapeutics revolutionize biotech with $135M and a blueprint from RNAi expert John Maraganore? 💡💊 Exciting news as City Therapeutics takes the biotech world by storm, opening its doors with a hefty $135 million funding, and groundbreaking work led by none other than RNAi expert, John Maraganore Ph.D. A significant force in the RNAi space, Maraganore's involvement promises to give this venture not just robust financial backing but also incredible scientific credibility. Their goal to improve health by developing next-generation therapies is innovative indeed. It's thrilling how quickly transformative technologies like these are breaking ground. Imagine limitless possibilities if science can leverage their efforts successfully! This story represents not just ground-breaking science but also the power of collaboration in our tech-infused world. Let's take this as our cue - we should look for opportunities for innovation & ignite corporate transformation! 🚀 Don't get left behind in this fast-paced race towards advancement; adopt AI solutions & automation to drive growth in your venture today! Book a meeting with us now: https://lnkd.in/gH39iDY3 Become part of our dynamic community of 160K+ corporate decision-makers, investors & groundbreaking founders - collaborating, learning together and transforming strategies into successful ventures! Keep innovating because change is not only coming – it’s here: https://lnkd.in/eEPzmzBR. #CityTherapeutics #JohnMaraganore #RNAiTech #BiotechRevolution #CollaborativeInnovation #NextGenerationTherapies #CorporateTransformation #AIInBusiness #StartupAccess #IgniteInnovation.

Could City Therapeutics revolutionize biotech with $135M and a blueprint from RNAi expert John Maraganore? 💡💊 Exciting news as City Therapeutics takes the biotech world by storm, opening its doors with a hefty $135 million funding, and groundbreaking work led by none other than RNAi expert, John Maraganore Ph.D. A significant force in the RNAi space, Maraganore's involvement promises to give this venture not just robust financial backing but also incredible scientific credibility. Their goal to improve health by developing next-generation therapies is innovative indeed. It's thrilling how quickly transformative technologies like these are breaking ground. Imagine limitless possibilities if science can leverage their efforts successfully! This story represents not just ground-breaking science but also the power of collaboration in our tech-infused world. Let's take this as our cue - we should look for opportunities for innovation & ignite corporate transformation! 🚀 Don't get left behind in this fast-paced race towards advancement; adopt AI solutions & automation to drive growth in your venture today! Book a meeting with us now: https://lnkd.in/gH39iDY3 Become part of our dynamic community of 160K+ corporate decision-makers, investors & groundbreaking founders - collaborating, learning together and transforming strategies into successful ventures! Keep innovating because change is not only coming – it’s here: https://lnkd.in/eEPzmzBR. #CityTherapeutics #JohnMaraganore #RNAiTech #BiotechRevolution #CollaborativeInnovation #NextGenerationTherapies #CorporateTransformation #AIInBusiness #StartupAccess #IgniteInnovation.

Could City Therapeutics revolutionize biotech with $135M and a blueprint from RNAi expert John Maraganore? 💡💊 Exciting news as City Therapeutics takes the biotech world by storm, opening its doors with a hefty $135 million funding, and groundbreaking work led by none other than RNAi expert, John Maraganore Ph.D. A significant force in the RNAi space, Maraganore's involvement promises to give this venture not just robust financial backing but also incredible scientific credibility. Their goal to improve health by developing next-generation therapies is innovative indeed. It's thrilling how quickly transformative technologies like these are breaking ground. Imagine limitless possibilities if science can leverage their efforts successfully! This story represents not just ground-breaking science but also the power of collaboration in our tech-infused world. Let's take this as our cue - we should look for opportunities for innovation & ignite corporate transformation! 🚀 Don't get left behind in this fast-paced race towards advancement; adopt AI solutions & automation to drive growth in your venture today! Book a meeting with us now: https://lnkd.in/gH39iDY3 Become part of our dynamic community of 160K+ corporate decision-makers, investors & groundbreaking founders - collaborating, learning together and transforming strategies into successful ventures! Keep innovating because change is not only coming – it’s here: https://lnkd.in/eEPzmzBR. #CityTherapeutics #JohnMaraganore #RNAiTech #BiotechRevolution #CollaborativeInnovation #NextGenerationTherapies #CorporateTransformation #AIInBusiness #StartupAccess #IgniteInnovation.

Could City Therapeutics revolutionize biotech with $135M and a blueprint from RNAi expert John Maraganore? 💡💊 Exciting news as City Therapeutics takes the biotech world by storm, opening its doors with a hefty $135 million funding, and groundbreaking work led by none other than RNAi expert, John Maraganore Ph.D. A significant force in the RNAi space, Maraganore's involvement promises to give this venture not just robust financial backing but also incredible scientific credibility. Their goal to improve health by developing next-generation therapies is innovative indeed. It's thrilling how quickly transformative technologies like these are breaking ground. Imagine limitless possibilities if science can leverage their efforts successfully! This story represents not just ground-breaking science but also the power of collaboration in our tech-infused world. Let's take this as our cue - we should look for opportunities for innovation & ignite corporate transformation! 🚀 Don't get left behind in this fast-paced race towards advancement; adopt AI solutions & automation to drive growth in your venture today! Book a meeting with us now: https://lnkd.in/gH39iDY3 Become part of our dynamic community of 160K+ corporate decision-makers, investors & groundbreaking founders - collaborating, learning together and transforming strategies into successful ventures! Keep innovating because change is not only coming – it’s here: https://lnkd.in/eEPzmzBR. #CityTherapeutics #JohnMaraganore #RNAiTech #BiotechRevolution #CollaborativeInnovation #NextGenerationTherapies #CorporateTransformation #AIInBusiness #StartupAccess #IgniteInnovation.

Could City Therapeutics revolutionize biotech with $135M and a blueprint from RNAi expert John Maraganore? 💡💊 Exciting news as City Therapeutics takes the biotech world by storm, opening its doors with a hefty $135 million funding, and groundbreaking work led by none other than RNAi expert, John Maraganore Ph.D. A significant force in the RNAi space, Maraganore's involvement promises to give this venture not just robust financial backing but also incredible scientific credibility. Their goal to improve health by developing next-generation therapies is innovative indeed. It's thrilling how quickly transformative technologies like these are breaking ground. Imagine limitless possibilities if science can leverage their efforts successfully! This story represents not just ground-breaking science but also the power of collaboration in our tech-infused world. Let's take this as our cue - we should look for opportunities for innovation & ignite corporate transformation! 🚀 Don't get left behind in this fast-paced race towards advancement; adopt AI solutions & automation to drive growth in your venture today! Book a meeting with us now: https://lnkd.in/gs_bUHEB Become part of our dynamic community of 160K+ corporate decision-makers, investors & groundbreaking founders - collaborating, learning together and transforming strategies into successful ventures! Keep innovating because change is not only coming – it’s here: https://lnkd.in/e2dexVbS. #CityTherapeutics #JohnMaraganore #RNAiTech #BiotechRevolution #CollaborativeInnovation #NextGenerationTherapies #CorporateTransformation #AIInBusiness #StartupAccess #IgniteInnovation.

🚀ARCH Venture Partners has just announced it closed its $3B Fund XIII, positioning itself as a key player in driving the next wave of biotech innovation. 🌱 This fund will fuel early-stage biotechs focusing on AI-driven drug discovery, cell and gene therapies, oncology, rare diseases, and immunology. But ARCH isn’t the only fund making headlines this year. Here’s how others are shaping up: 💡 Other Notable Funds Raised in 2024: ➡️ Flagship Pioneering raised a $3.4B fund, targeting early-stage biotech companies with a strong emphasis on therapeutics and diagnostics innovations. ➡️ Scion Life Sciences launched a fund over $300M, aiming to build a select number of durable startups with ample funding and resources, similar to the strategies used by Flagship and ARCH. They focus on biopharma, medtech, and diagnostics, and aim to scale this fund toward $1B. ➡️ Sands Capital closed its $560M third life sciences fund. As a crossover fund, it invests in clinical-stage companies developing therapeutics, diagnostics, and digital health solutions. ➡️ J.P. Morgan’s Private Financing Arm introduced a $500M biotech fund, targeting early to growth-stage biotechs with a focus on therapeutics, platform technologies, and health tech. ➡️ Foresite Capital completed a $900M sixth fund, backing companies like Xaira and Alumis, with an emphasis on AI-driven drug discovery, immunology, and precision medicine. These substantial fundraises reflect increased confidence in biotech's potential to revolutionize healthcare through AI, precision medicine, and advanced therapies. 🔬 🧠🌩️ What trends do you think will define biotech investments in the coming years? #BiotechInvesting #VentureCapital #BiotechFunding #AI #PrecisionMedicine

Great news from Boston: Venture Leader Biotech Allegria Therapeutics, currently with the Swiss National Startup Team in the US, announces USD 3.5 million in seed funding raised. Applause on the deal to Maria Van Dongen and her ambitious team! https://lnkd.in/gZJJPbvM The funding was provided by Forty51 Ventures. About: Allegria Therapeutics' R&D activities focus on mast cells as mediators of allergy and inflammatory diseases, a class of indications that constitutes an increasing burden worldwide. More and more patients suffer from these conditions' impact on their quality of life. The associated socioeconomic burden is huge, and despite the growing medical need, the treatment options are still notoriously limited with overall poor outcomes. For more information and updates on Allegria Therapeutics and the Venture Leaders Biotech 2024, follow #VLeadersBioech on social media and on https://lnkd.in/dsdBqy2E. Should you be in Boston tomorrow, get your invitation to join us at Swissnex for the the Biotech Pitchfest https://lnkd.in/dfNJrfs5 and meet the full Team. This year's Venture Leaders Biotech program is co-organized by Venturelab and Swissnex in Boston and New York and supported by Debiopharm, EPFL, ETH Zürich, Hansjörg Wyss, Kellerhals Carrard Startup & VC Desk, Novartis, Swiss Biotech Association and VISCHER. #VLeadersBiotech #SwissStartups